Zen Investments

Zenith Epigenetics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetics-based therapies for the treatment of cancer and other diseases with high unmet medical needs. The company's lead program, ZEN-3694, is a selective bromodomain and extra-terminal domain (BET) inhibitor currently being evaluated in multiple Phase 2 clinical trials. Zenith's therapeutic approach involves modulating gene expression by targeting epigenetic readers, which play a crucial role in the regulation of oncogenic pathways. The company frequently collaborates with major pharmaceutical partners and academic institutions to explore combination therapies, particularly in resistant oncology settings such as metastatic castration-resistant prostate cancer.